According to a study in JAMA, COPD patient treated with LAMA/LABA combination therapy had fewer exacerbations, MPR reports.

Compared with LABA plus ICS, treatment with LAMA plus LABA is associated with fewer exacerbation events in patients with COPD and greater improvement forced expiratory volume in the first second of expiration, measured in the morning before the first dose of medication.

There were no differences in the incidence of severe adverse events or all-cause mortality between the groups. The findings are aligned with the GOLD 2017 guidelines, which recommended LAMA plus LABA as the second choice after single bronchodilator therapies for more symptomatic patients with low risk of COPD exacerbation events and less symptomatic patients with frequent exacerbation events.